
    
      Induction therapy:

        -  Imatinib 200-400 mg p.o. daily x 10 days, Days 1-10 (see dose escalation scheme in
           Section 5.4 below).

        -  Mitoxantrone 10 mg/m2 daily x 5 days, Days 4-8.

        -  Etoposide 100 mg/m2 daily x 5 days, Days 4-8.

        -  Cytarabine 1.5 grams/m2 q12h x 4 doses, Days 9-10 (for patients aged 60 years and over,
           1.0 gram/m2).

      Only one induction course will be permitted. Only patients achieving CR will proceed to
      consolidation and maintenance.

      Consolidation therapy, maximum 2 cycles (for patients achieving CR):

        -  Imatinib 200-400 mg p.o. daily x 8 days, Days 1-8 (see dose escalation scheme in Section
           5.4 below).

        -  Mitoxantrone 12 mg/m2 daily x 2 days, Days 4-5.

        -  Cytarabine 3 grams/m2 q12h x 6 doses, Days 4,6,8. For patients aged 60 years and over,
           the dose will be reduced to 1.5 grams/m2.

      Maintenance therapy (for patients still in CR at end of consolidation):

      Imatinib 600 mg p.o. daily, until relapse or toxicity (see dose modification criteria in
      Section 5.6.6 below). Patients must receive at least one consolidation cycle before being
      permitted to proceed to maintenance therapy (see Section 5.6 for details). Maintenance
      therapy with imatinib will be provided for a maximum period of 1 year.

      Dose escalation scheme:

      Imatinib will be used during induction and consolidation at one of the following dose levels:

      Level -1 100 mg daily Level 1 200 mg daily Level 2 300 mg daily Level 3 400 mg daily
    
  